DOCSLIB.ORG

Project Retrosight: Understanding the Returns from Cardiovascular And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Project Retrosight: Understanding the Returns from Cardiovascular And WORKING P A P E R Project Retrosight Understanding the returns from cardiovascular and stroke research Case Studies ALEXANDRA POLLITT, STEVEN WOODING, STEPHEN HANNEY, MARTIN BUXTON AND JONATHAN GRANT WR-836-RS March 2011 Prepared on behalf of the Project Retrosight Team Approved for public release, distribution unlimited This product is part of the RAND Europe working paper series. RAND working papers are intended to share researchers’ latest findings and to solicit informal peer review. They have been approved for circulation by RAND Europe but have not been formally edited or peer reviewed. Unless otherwise indicated, working papers can be quoted and cited without permission of the author, provided the source is clearly referred to as a working paper. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. is a registered trademark. Preface This report presents a set of 29 case studies of cardiovascular and stroke research grants funded in three countries between 1989 and 1993. The case studies focused on the individual grants but considered the development of the investigators and ideas involved in the research projects from initiation to the present day. Basic biomedical and clinical cardiovascular and stroke research grants awarded in Australia, Canada and the UK were selected through a stratified random selection approach that aimed to include both high- and low-impact grants. Case studies were constructed around the Payback Framework1, a research evaluation framework that is both a tool for evaluating a range of potential outputs from research and a logic model that provides a mechanism for conceptualising the process through which outputs are created. The structured case studies were used to assess the impact of the research grants in detail and to draw conclusions about the relationship between impact and a range of factors. The key messages from the project are as follows. The cases reveal that a large and diverse range of impacts arose from the 29 grants studied. There are variations between the impacts derived from basic biomedical and clinical research. There is no correlation between knowledge production and wider impacts. The majority of economic impacts identified come from a minority of projects. We identified factors that appear to be associated with high and low impact. This report presents the case studies. As far as possible, they are presented in the form used in the analysis. Case studies were initially approved by the PI for the research examined and each case study was then peer reviewed by independent researchers in the cardiovascular and stroke field. These reviews were used by the rating panel in assessing the impacts of the research described. Twenty-four of the case studies were reviewed by two independent researchers; for the remaining five we were only able to secure one reviewer in each case. Buxton, M., and S. Hanney. “How can payback from health services research be assessed?” Journal of Health Services Research and Policy 1 (1996): 35–43. i The Policy Report2 presents the project’s findings and their implications for policy, and the Methodology Report3 provides a detailed account of the methodology used, including the review process. This work was led by RAND Europe in collaboration with the Health Economics Research Group (HERG) at Brunel University. RAND Europe is an independent not-for- profit policy research organisation that serves the public interest by improving policy- making and informing public debate. The Health Economics Research Group is a Specialist Research Institute of Brunel University dedicated to conducting accessible, policy-relevant research of a high academic quality focused on improving the efficiency and cost-effectiveness of resources devoted to health care and to research. For more information about RAND Europe or this document, please contact: Steven Wooding Research Leader RAND Europe Westbrook Centre, Milton Road Cambridge, CB4 1YG United Kingdom Email: [email protected] or [email protected] 2 Wooding, S., S. Hanney, A. Pollitt, M. Buxton, and J. Grant. Project Retrosight. Understanding the returns from cardiovascular and stroke research: Policy Report. Cambridge, UK: RAND Europe, MG-1079-RS, 2011. 3Pollitt, A., S. Wooding, S. Hanney, M. Buxton, and J. Grant. Project Retrosight. Understanding the returns from cardiovascular and stroke research: Methodology Report. Cambridge, UK: RAND Europe, TR-925-RS, 2011 ii Contents Preface ............................................................................................................. i Acknowledgements and detailed authorship .................................................................. v CHAPTER 1 To conduct studies of a high density lipoprotein conversion factor ............................................................................................... 1 CHAPTER 2 Fibrillin deficiency in Marfan syndrome and overlapping syndromes (familial mitral valve prolapse, familial ascending aortic aneurysm): diagnosis and risk stratification ......................... 33 CHAPTER 3 ‘Heartstart Scotland’ – analysis of the results of a national programme .................................................................................... 55 CHAPTER 4 Haemostatic markers in acute transient ischaemic attacks .............. 83 CHAPTER 5A follow-up study of heart attack patients ................................... 103 CHAPTER 6 Coronary lesions and vasoactivity ................................................ 131 CHAPTER 7 The organisation and nature of formed elements within the paracellular clefts of capillary endothelia ..................................... 155 CHAPTER 8 Low-intensity warfarin and thrombosis ....................................... 179 CHAPTER 9 Analysis of the glucose transporter compliment and function in metabolically important tissues of the Milan hypertensive rat ................................................................................................ 197 CHAPTER 10 The role of coagulation and fibrinolysis in the pathogenesis of recurrent stroke ............................................................................ 219 CHAPTER 11 Nimodipine binding in cerebral ischaemia ................................... 237 CHAPTER 12 Genetic and cellular determinants of increased growth of vascular smooth muscle in spontaneously hypertensive rats ......... 261 iii CHAPTER 13 The study of the role of the regulatory gene, Mlx1, in cardiac development and disease, and the creation of animal models for myocardial dysfunction .......................................................... 281 CHAPTER 14 Effect of simulated stroke on developing astrocytes ..................... 305 CHAPTER 15 The effects of alcohol consumption on blood pressure, plasma lipoprotein cholesterol fractions and sympathetic nervous system function in man ................................................................ 323 CHAPTER 16 Electrophysiologic properties of cardiac myocytes in cardiomyopathy ........................................................................... 347 CHAPTER 17 To study the effects of angiotensin-converting enzyme inhibitors on tissue and cardiac angiotensin-converting enzyme ......................................................................................... 371 CHAPTER 18 Vasoactive substances and pathogenesis of essential hypertension ................................................................................ 399 CHAPTER 19 Immunoelectron microscopy of amine and peptide synapses on sympathetic preganglionic neurons ......................................... 419 CHAPTER 20 Right-hemisphere stroke: incidence, severity and recovery of language disorders ....................................................................... 439 CHAPTER 21 To study secondary prevention of hypertension ........................... 459 CHAPTER 22 The effects of lean meat diets on plasma lipids and haemostatic functions .................................................................. 487 CHAPTER 23 Cell–cell interactions in the disposition of natriuretic peptides in the bovine chromaffin cells ...................................................... 525 CHAPTER 24 Is hepatic synthesis and secretion of lecithin-cholesterol acyltransferase (LCAT) linked to lipoprotein production by the liver and intestine? ................................................................. 547 CHAPTER 25 Modulation of nitric oxide biosynthesis by polyamines ............... 563 CHAPTER 26 Antiarrhythmic drug receptor ...................................................... 577 CHAPTER 27 Biobehavioural influences on hypertension and atherosclerosis .............................................................................. 597 CHAPTER 28 Prolonged heart and lung allograft preservation .......................... 623 CHAPTER 29 Stroke prevention in the elderly in primary care .......................... 649 iv Acknowledgements and detailed authorship We would like to start by acknowledging all the scientists who were willing to act as the participants for this study, particularly the principal investigators of the 29 case study grants. The study would clearly have been impossible without them. This study was initiated with internal funding from RAND Europe and HERG, with continuing funding from the UK National Institute for Health Research, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada and the National Heart Foundation of Australia. The UK Stroke
Load more

Recommended publications
  • Unrestricted Immigration and the Foreign Dominance Of
    Unrestricted Immigration and the Foreign Dominance of United States Nobel Prize Winners in Science: Irrefutable Data and Exemplary Family Narratives—Backup Data and Information Andrew A. Beveridge, Queens and Graduate Center CUNY and Social Explorer, Inc. Lynn Caporale, Strategic Scientific Advisor and Author The following slides were presented at the recent meeting of the American Association for the Advancement of Science. This project and paper is an outgrowth of that session, and will combine qualitative data on Nobel Prize Winners family histories along with analyses of the pattern of Nobel Winners. The first set of slides show some of the patterns so far found, and will be augmented for the formal paper. The second set of slides shows some examples of the Nobel families. The authors a developing a systematic data base of Nobel Winners (mainly US), their careers and their family histories. This turned out to be much more challenging than expected, since many winners do not emphasize their family origins in their own biographies or autobiographies or other commentary. Dr. Caporale has reached out to some laureates or their families to elicit that information. We plan to systematically compare the laureates to the population in the US at large, including immigrants and non‐immigrants at various periods. Outline of Presentation • A preliminary examination of the 609 Nobel Prize Winners, 291 of whom were at an American Institution when they received the Nobel in physics, chemistry or physiology and medicine • Will look at patterns of
    [Show full text]
  • MED C-LIVE Transcript
    JUNE 2020 Mario Capecchi, Ph.D. NOT FOR PUBLIC DISTRIBUTION Michael Keel My name is Michael Keel from New Jersey. And it is my honor to introduce Dr. Mario Capecchi. Dr. Capecchi is the Distinguished Professor of Human Genetics at the University of Utah School of Medicine. He is best known for his groundbreaking work in gene targeting, in mass embryo derived stem cells. He was awarded the Nobel Prize in Physiology for Medicine, for his work in finding ways to manipulate the mammalian genome by changing mammals’ genes. His research interests include analysis of neural development in mammals, gene therapy, and production of murine models of human genetic diseases, from cancer to neuropsychiatric disorders. Dr. Capecchi, welcome to the Congress of Future Medical Leaders. Dr. Capecchi Thank you. First of all, welcome to the Medical Leaders’ Congress. It's a pleasure to be here. My name is Mario. I'm going to be talking about gene targeting. Next slide please. My laboratory has developed a technology called gene targeting that allows you to change any gene in any conceivable manner in a living creature, such as a mouse. Next slide. Why do we do gene targeting? Next slide. There are many reasons, but they boil down to two. One is basic research and the other is applied research. In basic research, you investigate the biology of an animal. For example, how do you make a limb or a heart or a brain? Those are basic research questions. The other is applied research. That is we can use gene targeting to generate mice with human diseases.
    [Show full text]
  • 2004 Albert Lasker Nomination Form
    albert and mary lasker foundation 110 East 42nd Street Suite 1300 New York, ny 10017 November 3, 2003 tel 212 286-0222 fax 212 286-0924 Greetings: www.laskerfoundation.org james w. fordyce On behalf of the Albert and Mary Lasker Foundation, I invite you to submit a nomination Chairman neen hunt, ed.d. for the 2004 Albert Lasker Medical Research Awards. President mrs. anne b. fordyce The Awards will be offered in three categories: Basic Medical Research, Clinical Medical Vice President Research, and Special Achievement in Medical Science. This is the 59th year of these christopher w. brody Treasurer awards. Since the program was first established in 1944, 68 Lasker Laureates have later w. michael brown Secretary won Nobel Prizes. Additional information on previous Lasker Laureates can be found jordan u. gutterman, m.d. online at our web site http://www.laskerfoundation.org. Representative Albert Lasker Medical Research Awards Program Nominations that have been made in previous years may be updated and resubmitted in purnell w. choppin, m.d. accordance with the instructions on page 2 of this nomination booklet. daniel e. koshland, jr., ph.d. mrs. william mccormick blair, jr. the honorable mark o. hatfied Nominations should be received by the Foundation no later than February 2, 2004. Directors Emeritus A distinguished panel of jurors will select the scientists to be honored. The 2004 Albert Lasker Medical Research Awards will be presented at a luncheon ceremony given by the Foundation in New York City on Friday, October 1, 2004. Sincerely, Joseph L. Goldstein, M.D. Chairman, Awards Jury Albert Lasker Medical Research Awards ALBERT LASKER MEDICAL2004 RESEARCH AWARDS PURPOSE AND DESCRIPTION OF THE AWARDS The major purpose of these Awards is to recognize and honor individuals who have made signifi- cant contributions in basic or clinical research in diseases that are the main cause of death and disability.
    [Show full text]
  • Eighty Years of Fighting Against Cancer in Serbia Ovarian Cancer Vaccine
    News Eighty years of fighting against cancer Recent study by Kunle Odunsi et al., Roswell Park Cancer Institute, Buffalo, in Serbia New York, USA, showed an effects of vaccine based on NY-ESO-1, a „cancer This year on December 10th, Serbian society for the fight against cancer has testis“ antigen in preventing the recurrence of ovarian cancer. NY-ESO-1 is a ovarian celebrated the great jubilee - 80 years of its foundation. The celebration took „cancer-testis“ antigen expressed in epithelial cancer (EOC) and is place in Crystal Room of Belgrade’s Hyatt hotel, gathering many distinguished among the most immunogenic tumor antigens defined to date. presence + guests from the country and abroad. This remarkable event has been held Author’s previous study point to the role of of intraepithelial CD8 - under the auspices of the President of Republic of Serbia, Mr. Boris Tadić. infiltrating T lymphocytes in tumors that was associated with improved survival of The whole ceremony was presided by Prof. Dr. Slobodan Čikarić, actual presi- patients with the disease. The NY-ESO-1 peptide epitope, ESO157–170, is recog- + + dent of Society, who greeted guests and wished them a warm welcome. Than nized by HLA-DP4-restricted CD4 T cells and HLA-A2- and A24-restricted CD8 + followed the speech of Serbian health minister, Prof. Dr. Tomica Milosavljević T cells. To test whether providing cognate helper CD4 T cells would enhance who pointed out the importance of preventive measures and public education the antitumor immune response, Odunsi et al., conducted a phase I clinical trial along with timely diagnosis and multidisciplinary treatment in global fight of immunization with ESO157–170 mixed with incomplete Freund's adjuvant + against cancer in Serbia.
    [Show full text]
  • I. Hox Genes 2
    School ofMedicine Oregon Health Sciences University CERTIFICATE OF APPROVAL This is certify that the Ph.D. thesis of WendyKnosp has been approved Mentor/ Advisor ~ Member Member QUANTITATIVE ANALYSIS OF HOXA13 FUNCTION IN THE DEVELOPING LIMB By Wendy M. lt<nosp A DISSERTATION Presented to the Department of Molecular and Medical Genetics and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy August 2006 TABLE OF CONTENTS LIST OF FIGURES iv LIST OF ABBREVIATIONS vii ACKNOWLEDGEMENTS X ABSTRACT xii CHAPTER 1: Introduction 1 I. Hox genes 2 A. Discovery of Hox genes in Drosophila melanogaster 2 B. Hox cluster colinearity and conservation 7 C. Human Hox mutations 9 D. Hoxa13: HFGS and Guttmacher syndromes 10 II. The Homeodomain 12 A. Homeodomain structure 12 B. DNA binding 14 Ill. Limb development 16 A. Patterning of the limb axes 16 B. Digit formation 20 C. lnterdigital programmed cell death 21 IV. BMPs and limb development 23 A. BMP signaling in the limb 23 B. BMP target genes 27 V. Hoxa13 and embryonic development 30 A. The Hoxa13-GFP mouse model 30 B. Hoxa13 mutant phenotypes 34 C. HOXA 13 homeodomain 35 D. HOXA 13 protein-protein interactions 36 E. HOXA 13 target genes 37 VI. Hypothesis and Rationale 39 CHAPTER 2: HOXA13 regulates Bmp2 and Bmp7 40 I. Abstract 42 II. Introduction 43 Ill. Results 46 IV. Discussion 69 v. Materials and Methods 75 VI. Acknowledgements 83 11 CHAPTER 3: Quantitative analysis of HOXA13 function 84 HOXA 13 regulation of Sostdc1 I.
    [Show full text]
  • October 2, 2001, NIH Record, Vol. LIII, No. 20
    R Still The Second Best Thing About Payday Translating the Histone Code: A H G H L 1,G H T, S Tale of Tails at Stetten Talk Attacks on U.S. Change Life at NIH By Rich McManus By Alison Davis Security Beefed Up News stories appearing over the last year he transition from peacetime's reliable routine to wartime On Campus would have everyone believe that scientists anxiety took place in only minutes as NTH employees came have-once and for all~racked the human Tto work on an otherwise spectacular late summer morning genetic code. Indeed, two teams of 50th Anniversary Sept. 11 and scientists have already published a draft For NINOS, NIMH discovered by 9:45- sequence of our 3-billion-unit jumble of via office televisions, DNA "letters." But t he task of thoroughly radio, the web, deciphering the code's protein-making phone calls and Grantees Win hallway conversa­ instructions-something our bodies do Lasker Award SEE STETTEN LECTURE, PAGE 2 tions-that terror­ ism on an almost unimaginable scale Kolb To Give was taking place in Pittman Lecture New York City and in the heart of Washington, D.C. Fall Computer The workday froze Courses Offered as workers tuned in to the news-the World Trade Center towers in flames, Flag flies at half-mast in tragedy's wake. Outdoor Film and smoke rising from behind the Old Executive Office buiJding Dr. C. David Allis to give Stetten Lecture. Festival a Big Hit near the White House. Summer Jobs into Permanent Posts In the OD Office of Communications and Public Liaison in Bldg.
    [Show full text]
  • Chapter 18: Heart Disease and Diabetes
    CHAPTER 18 HEART DISEASE AND DIABETES Elizabeth Barrett-Connor, MD, Deborah Wingard, PhD, Nathan Wong, PhD, and Ron Goldberg, MD Dr. Elizabeth Barrett-Connor is Distinguished Professor, Division of Epidemiology, Department of Family Medicine and Public Health at the University of California, San Diego, La Jolla, CA. Dr. Deborah Wingard is Professor, Division of Epidemiology, Department of Family Medicine and Public Health at the University of California, San Diego, La Jolla, CA. Dr. Nathan Wong is Professor and Director of the Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, Irvine, CA. Dr. Ron Goldberg is Professor of Medicine and Biochemistry and Molecular Biology, Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL. SUMMARY Heart disease remains a major cause of morbidity and mortality in type 2 diabetes and is estimated to account for 10%–11% of all vascular deaths. Surveys of the U.S. population have demonstrated an age-standardized differential for heart disease in adults with mostly type 2 diabetes that varies from 1.9 to 2.5. The age-standardized prevalence is about 50% higher in men than women overall and for most categories of heart disease, except congestive heart failure. Although rates of diabetes are higher in nonwhites than in non-Hispanic whites, it should be noted that non-Hispanic whites with diabetes generally report heart disease rates about 50% higher than Hispanic subjects with diabetes, with an intermediate prevalence in non-Hispanic blacks. Despite an approximate doubling in type 2 diabetes prevalence from the 1980s to the 2010s, the prevalence of heart disease in diabetes has remained stable.
    [Show full text]
  • The Nobel Prize in Physiology Or Medicine 2007
    PRESS RELEASE 2007-10-08 The Nobel Assembly at Karolinska Institutet has today decided to award The Nobel Prize in Physiology or Medicine 2007 jointly to Mario R. Capecchi, Martin J. Evans and Oliver Smithies for their discoveries of “principles for introducing specific gene modifications in mice by the use of embryonic stem cells” SUMMARY This year’s Nobel Laureates have made a series of ground-breaking discoveries concerning embryonic stem cells and DNA recombination in mammals. Their discoveries led to the creation of an immensely powerful technology referred to as gene targeting in mice. It is now being applied to virtually all areas of biomedicine – from basic research to the development of new therapies. Gene targeting is often used to inactivate single genes. Such gene “knockout” experiments have elucidated the roles of numerous genes in embryonic development, adult physiology, aging and disease. To date, more than ten thousand mouse genes (approximately half of the genes in the mammalian genome) have been knocked out. Ongoing international efforts will make “knockout mice” for all genes available within the near future. With gene targeting it is now possible to produce almost any type of DNA modification in the mouse genome, allowing scientists to establish the roles of individual genes in health and disease. Gene targeting has already produced more than five hundred different mouse models of human disorders, including cardiovascular and neuro-degenerative diseases, diabetes and cancer. Modification of genes by homologous recombination Information about the development and function of our bodies throughout life is carried within the DNA. Our DNA is packaged in chromosomes, which occur in pairs – one inherited from the father and one from the mother.
    [Show full text]
  • Langley 1 William H. Knight a Village That Is Noted for Its Woolen Twist and Twill, `Tis the Pride of Massachusetts
    Langley 1 William H. Knight A village that is noted For its woolen twist and twill, `Tis the pride of Massachusetts And they call it Saxonville. Excerpt from “Saxonville” by J.P., Date Unknown As a lifelong resident of Massachusetts, regions whose affiliations are not readily apparent always intrigue me. I had heard of Saxonville over the years and wondered about it. Was it a town unto itself or part of another community? Where did the name come from? Why was it significant enough to warrant its own historical preservation commission? Saxonville is, in fact, the oldest section of the town of Framingham. Its establishment as a village with its own name was the result of the talent, vision, and perseverance of immigrant William H. Knight whose work turned what was originally known as Stone’s End into Saxonville. Industry along the Sudbury River followed the needs of this region just 20 miles outside of Boston. Settler John Stone was the first to harness the power of the river by erecting a gristmill at the Great Falls of the Sudbury River in 1650, which endured until 1795 when it was converted into a sawmill. In 1811, it was converted into a cotton mill under the auspices of the Framingham Manufacturing Company on the heels of nearby Westborough native Eli Whitney’s invention of the cotton gin. However, “The New England textile industry soon realized that cotton was not king.” (Herring, 2000, p. X) The chilly climate of the region required a warmer material for clothing and bedding in the form of wool.
    [Show full text]
  • Framingham Contribution to Cardiovascular Disease
    [Downloaded free from http://www.heartviews.org on Wednesday, October 12, 2016, IP: 62.193.78.199] History of Medicine Framingham Contribution to Cardiovascular Disease Rachel Hajar, M.D. Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar round 17.5 million people die each year from and is now on its third generation of participants. Much cardiovascular diseases (CVDs), an estimated of our appreciation of the pathophysiology of heart 31% of all deaths worldwide. This statistic is disease came from the results of studies from the FHS. A [1] expected to grow to more than 23.6 million by 2030. It established the traditional risk factors, such as high Of these deaths (17.5 million), estimated 7.4 million blood pressure, diabetes, and cigarette smoking for are due to coronary heart disease and 6.7 million are coronary heart disease. Framingham also spearheaded due to stroke.[1] Epidemiologic studies have played an the study of chronic noninfectious diseases in the USA important role in elucidating the factors that predispose and introduced preventive medicine. to CVD and highlighting opportunities for prevention. Most CVDs can be prevented by addressing behavioral ORIGINS OF THE FRAMINGHAM HEART risk factors such as tobacco use, unhealthy diet and STUDY obesity, physical inactivity, and harmful use of alcohol. CVDs are a group of disorders of the heart and In 2013, the FHS celebrated 65 years since its creation. blood vessels, and they include coronary heart disease, The investigation has provided substantial insight cerebrovascular disease, peripheral arterial disease; and into the epidemiology of CVD and its risk factors.
    [Show full text]
  • ILAE Historical Wall02.Indd 10 6/12/09 12:04:44 PM
    2000–2009 2001 2002 2003 2005 2006 2007 2008 Tim Hunt Robert Horvitz Sir Peter Mansfi eld Barry Marshall Craig Mello Oliver Smithies Luc Montagnier 2000 2000 2001 2002 2004 2005 2007 2008 Arvid Carlsson Eric Kandel Sir Paul Nurse John Sulston Richard Axel Robin Warren Mario Capecchi Harald zur Hauser Nobel Prizes 2000000 2001001 2002002 2003003 200404 2006006 2007007 2008008 Paul Greengard Leland Hartwell Sydney Brenner Paul Lauterbur Linda Buck Andrew Fire Sir Martin Evans Françoise Barré-Sinoussi in Medicine and Physiology 2000 1st Congress of the Latin American Region – in Santiago 2005 ILAE archives moved to Zurich to become publicly available 2000 Zonismide licensed for epilepsy in the US and indexed 2001 Epilepsia changes publishers – to Blackwell 2005 26th International Epilepsy Congress – 2001 Epilepsia introduces on–line submission and reviewing in Paris with 5060 delegates 2001 24th International Epilepsy Congress – in Buenos Aires 2005 Bangladesh, China, Costa Rica, Cyprus, Kazakhstan, Nicaragua, Pakistan, 2001 Launch of phase 2 of the Global Campaign Against Epilepsy Singapore and the United Arab Emirates join the ILAE in Geneva 2005 Epilepsy Atlas published under the auspices of the Global 2001 Albania, Armenia, Arzerbaijan, Estonia, Honduras, Jamaica, Campaign Against Epilepsy Kyrgyzstan, Iraq, Lebanon, Malta, Malaysia, Nepal , Paraguay, Philippines, Qatar, Senegal, Syria, South Korea and Zimbabwe 2006 1st regional vice–president is elected – from the Asian and join the ILAE, making a total of 81 chapters Oceanian Region
    [Show full text]
  • Prevalence of Coronary Heart Disease by Age and Sex
    Prevalence of coronary heart disease by age and sex National Health and Nutrition Examination Survey: 2009–2012. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Prevalence of myocardial infarction by age and sex National Health and Nutrition Examination Survey: 2009–2012. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Annual number of adults per 1000 having diagnosed heart attack or fatal coronary heart disease (CHD) by age and sex Atherosclerosis Risk in Communities Surveillance: 2005–2011 and Cardiovascular Health Study. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Incidence of heart attack or fatal coronary heart disease by age, sex, and race Atherosclerosis Risk in Communities Surveillance: 2005–2011. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Incidence of myocardial infarction by age, sex, and race Atherosclerosis Risk in Communities Surveillance: 2005-2011. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Estimated 10-year coronary heart disease risk in adults 55 years of age according to levels of various risk factors (Framingham Heart Study). Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved. Prevalence of low coronary heart disease risk, overall and by sex National Health and Nutrition Examination Survey: 1971–2006. Mozaffarian D et al. Circulation. 2015;131:e29-e322 Copyright © American Heart Association, Inc. All rights reserved.
    [Show full text]